U.S. flag

An official website of the United States government

Display Settings:

Format

Send to:

Choose Destination
Tafasitamab (Minjuvi): CADTH Reimbursement Recommendation: Indication: In combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including diffuse large B-cell lymphoma arising from low grade lymphoma, who are not eligible for autologous stem cell transplant [Internet].

Tafasitamab (Minjuvi): CADTH Reimbursement Recommendation: Indication: In combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including diffuse large B-cell lymphoma arising from low grade lymphoma, who are not eligible for autologous stem cell transplant [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Oct.

Table of contents


Supplemental Content

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...